# Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)

> **NCT00290485** · PHASE2 · UNKNOWN · sponsor: **Maisonneuve-Rosemont Hospital** · enrollment: 50 (—)

## Conditions studied

- Gastrointestinal Stromal Tumors

## Interventions

- **DRUG:** Imatinib mesylate

## Key facts

- **NCT ID:** NCT00290485
- **Lead sponsor:** Maisonneuve-Rosemont Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-08
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 50 (—)
- **Last updated:** 2006-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00290485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00290485, "Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00290485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*